AXGN Axogen, Inc.

AXGN financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 805928 Exchange: Nasdaq SIC: 3845 (Electromedical & Electrotherapeutic Apparatus) Latest filing: 10-Q filed Jul 29, 2026 Data checked: Oct 21, 2026
Showing 3 of 16 annual and 0 of 63 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Large accelerated filer
Entity Type
Operating
Public Float
$430.70M (Jun 2025)
Industry (SIC)
3845 Electromedical & Electrotherapeutic Apparatus
Incorporated
MN
Fiscal Year End
December (1231)
Phone
(386) 462-6817
EIN
411301878
Headquarters
ALACHUA, FL, 32615
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names: LECTEC CORP /MN/ (1995–2011)

▼ Key Metrics (TTM)

As of Jun 30, 2026
Financials
Revenue
$251.17M
Net Income
$-33.55M
Total Assets
$304.86M
Total Equity
$256.26M
Total Debt
-
Free Cash Flow
$8.60M
Ratios
Gross Margin
74.6%
Operating Margin
-5.1%
Net Margin
-13.4%
Return on Equity
-13.1%
Return on Assets
-11%
Current Ratio
6.6x
FCF / Assets
2.8%

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

Axogen, Inc. generated $225.21M of revenue in fiscal 2025, with net loss of $15.70M and an operating cash inflow of $812.00K. Revenue of $225.21M sets the scale for evaluating how effectively sales translated into profit and cash during the year. Compared with $187.34M in fiscal 2024, revenue recorded a 20.2% year-over-year increase. The company reported diluted EPS of -$0.34, adding a shareholder-level measure to the absolute income figures considered below. Total assets stood at $221.69M, showing the scale of resources supporting revenue, earnings, liquidity, and financing. Revenue equaled 1.02x of total assets, indicating how much reported top-line activity the company produced relative to its period-end asset base.

Profitability

Gross profit was $167.35M, representing the portion of revenue remaining after the reported cost of revenue and before operating expenses. Gross margin was 74.3%, so that share of each revenue unit remained after the cost of revenue reported for the period. Operations produced a $7.85M operating loss before non-operating and tax effects. Relative to revenue, the operating deficit measured 3.5%, showing the shortfall after operating costs. After all below-operating-line items, the company recorded a net loss of $15.70M for the fiscal year. Net margin was -7.0%, reflecting a loss equal to 7.0% of reported revenue. The reported income-tax provision was $0.00, the amount recognized between pretax income and the final net-income result. The loss-to-equity relationship was 12.2%, placing the bottom-line deficit against shareholder capital. Relative to total assets, the net loss represented 7.1%. The net loss widened to $15.70M from $9.96M in fiscal 2024.

Liquidity and Capital Structure

At period end, the $221.69M asset base was financed through $92.84M of liabilities and $128.85M of equity. At period end, current assets of $120.42M compared with current liabilities of $23.56M, defining the company’s short-term resource position. The current ratio was 5.11x, with current assets exceeding current liabilities and providing a short-term liquidity cushion. Cash and equivalents totaled $35.55M, identifying the most liquid reported component available within the broader current-asset balance. The cash balance equaled 150.9% of current liabilities, showing how much near-term coverage came from cash alone. The company carried $48.39M of total debt at period end, which frames its leverage and debt-service burden. Against book equity, debt measured 0.38x, placing the company’s financial leverage in clear balance-sheet terms. Relative to total assets, debt measured 21.8%, showing how much of the asset base was matched by borrowing. The liabilities-to-assets relationship was 41.9%, placing reported obligations against the full positive asset balance. Measured against total assets, cash and equivalents represented 16.0%, a balance-sheet composition measure rather than a liquidity forecast. Compared with $203.73M in fiscal 2024, the current asset base moved 8.8% and finished higher. Book equity was 24.0% higher than fiscal 2024 equity of $103.91M, showing how shareholder capital changed year over year. Cash and equivalents were 29.0% higher than fiscal 2024 cash of $27.55M, showing the year-over-year change in liquid resources.

Cash Flow and Earnings Quality

Operating activities produced a cash inflow of $812.00K, giving the cash-flow counterpart to the accrual-based profit measures reported for the year. The cash-flow statement records $3.75M of capital expenditures, the investment amount considered after operating cash generation. Capital expenditures represented 461.2% of operating cash flow, leaving the remainder available as free cash flow. Operating cash flow and capital spending combined to leave a $2.93M cash deficit after capital spending. The free-cash-flow deficit equaled 1.3% of revenue, showing the post-investment cash shortfall relative to sales. The cash deficit after capital spending represented 1.3% of the period-end asset base.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for Axogen, Inc.
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
Revenue $225.21M $187.34M $159.01M
Cost of Revenue $57.86M $45.36M $37.14M
Gross Profit $167.35M $141.98M $121.87M
OPERATING EXPENSES
R&D Expense $32.89M $27.77M $27.34M
SG&A Expense $44.58M $39.04M $38.41M
Other Operating Expenses (derived) $97.74M $78.46M $77.58M
Operating Income $-7.85M $-3.29M $-21.46M
NON-OPERATING INCOME / EXPENSE
Interest Expense - - $2.84M
Other Income/Expense $167.00K $-199.00K $-437.00K
Income Tax $0 $0 $0
Net Income $-15.70M $-9.96M $-21.72M
PER SHARE & SUPPLEMENTAL
Diluted EPS $-0.34 $-0.23 $-0.51
Diluted Shares 46.05M 44.26M 42.88M
EBITDA $-1.19M $3.18M $-17.24M
Depreciation & Amortization $6.66M $6.47M $4.22M
Balance Sheet
ASSETS
Cash & Equivalents $35.55M $27.55M $31.02M
Short-term Investments $5.98M $5.93M $0
Accounts Receivable $26.17M $24.11M $25.15M
Inventory $42.37M $33.18M $23.02M
Other Current Assets $6.35M $2.45M $2.81M
Current Assets $120.42M $99.22M $88.00M
PP&E (Net) $81.78M $84.67M $88.73M
Intangible Assets $6.75M $5.58M $4.53M
Noncurrent Assets $101.27M $104.51M $108.82M
Total Assets $221.69M $203.73M $196.83M
LIABILITIES
Accounts Payable $2.89M $8.01M $11.77M
Other Current Liabilities $1.67M $2.05M $3.18M
Current Liabilities $23.56M $30.61M $30.43M
Long-term Debt $48.39M $47.50M $46.60M
Other Noncurrent Liabilities $141.00K $94.00K $0
Noncurrent Liabilities $69.28M $69.21M $70.73M
Total Liabilities $92.84M $99.82M $101.16M
EQUITY
Common Stock $472.00K $441.00K $431.00K
Additional Paid-in Capital $435.34M $394.73M $376.53M
Retained Earnings $-306.96M $-291.26M $-281.30M
Total Equity $128.85M $103.91M $95.67M
Total Liabilities & Equity $221.69M $203.73M $196.83M
SUPPLEMENTAL
Shares Outstanding 47.20M 44.15M 43.12M
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $812.00K $4.54M $-5.72M
Capital Expenditures $3.75M $3.10M $13.87M
Cash from Investing $-5.32M $-10.30M $19.25M
Cash from Financing $10.50M $2.29M $1.95M
Free Cash Flow $-2.93M $1.43M $-19.59M
Beginning Cash (CFS) $33.55M $37.03M $21.54M
Net Change in Cash $5.99M $-3.47M $15.49M
Effect of FX on Cash - - -
Calculated Ending Cash $39.55M $33.55M $37.03M
Cash per BS $35.55M $27.55M $31.02M
Cash scope difference (CFS − BS) $4.00M $6.00M $6.00M
Cash per CFS $39.55M $33.55M $37.03M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

What is Axogen, Inc.'s annual revenue?

Axogen, Inc. reported $251.17M in revenue for trailing twelve months (ending June 2026). Revenue figures are sourced from the company's annual SEC EDGAR filing.

Is Axogen, Inc. profitable?

No. Axogen, Inc. reported $-33.55M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.

Does Axogen, Inc. generate free cash flow?

Yes. Free cash flow was $8.60M for trailing twelve months. Operating cash flow was $15.05M.